In the comparison of in vivo efficacy among IMM47, IMM2515H (anti-PD-L1 antibody), IMM2510 (VEGF × PD-L1 bispecific Ab) and Tislelizumab all at a dose of 2 mg/kg, IMM47 demonstrates the best anti-tumor activity with a complete response rate of 83%, much better than the best of the rest, Tislelizumab, with a CR rate of 33% (Fig. 5A). This evidence concerns the gene VEGFA and neoplasm.